LA JOLLA, Calif., Jan. 7 /PRNewswire/ -- SIBIA Neurosciences, Inc.
(Nasdaq: SIBI) today announced the successful completion of a seven day
multiple dose Phase 1 study of SIB-1553A, its subtype-selective nicotinic
agonist, and the initiation of a Phase 2 study with the compound in
Alzheimer's disease patients.
In the Phase 1 multiple dose study, SIB-1553A was well tolerated, no
significant adverse events were observed, and it exhibited linear
pharmacokinetics. As in the previous Phase 1 single-dose study, central
nervous system activity was demonstrable by quantitative EEG. In addition,
SIB-1553A appeared to enhance performance in behavioral tests of attention and
cognition.
Jeffrey McKelvy, Ph.D., SIBIA's Chief Scientific Officer, stated, "After
repeat dose testing in normal subjects, SIB-1553A continues to be
well-tolerated and shows evidence of positive behavioral effects. On the
basis of the behavioral effects observed in normal subjects, SIBIA has
initiated a Phase 2 study in Alzheimer's disease patients, using similar
outcome measures. In this new study, we hope to extend our understanding of
the therapeutic potential of SIB-1553A. Using a trial design in which
patients serve as their own controls, we can evaluate the acute cognitive
effects of SIB-1553A with a relatively small number of patients. This is part
of our strategy of demonstrating therapeutic relevance through clinical
pharmacology."
SIBIA Neurosciences, Inc. is engaged in the discovery and development of
novel small molecule therapeutics for the treatment of neurodegenerative,
neuropsychiatric and neurological disorders, many of which have large patient
populations and represent critical unmet medical needs. SIBIA is a leader in
the development of proprietary drug discovery platforms that combine key tools
necessary for modern drug discovery, including genomics, high throughput
screening, advanced combinatorial chemistry techniques and pharmacology. The
Company's proprietary molecular targets and drug candidates, together with its
drug discovery technologies and research expertise, have enabled the Company
to establish several corporate collaborations, which currently include
Bristol-Myers Squibb Company and Meiji Seika Kaisha, Ltd., and multiple
technology licensing arrangements.
This press release contains forward-looking statements that involve risks
and uncertainties. Actual results could differ materially from those
discussed herein. These risks and uncertainties include whether SIBIA will be
able to meet its development goals with respect to its drug candidates,
whether SIBIA's clinical trials will yield favorable results, the new and
uncertain state of SIBIA's technologies, SIBIA's future capital needs and the
uncertainty of receiving additional funding, uncertainties regarding patents
and proprietary rights, and other research, development and market risks.
These and other risks and uncertainties are more fully set forth in SIBIA's
most recently filed Forms 10-Q and 10-K.
SOURCE SIBIA Neurosciences, Inc.
 back to top
Related links:
http://www.sibia.com
CONTACT:
Jeffrey F. McKelvy, Ph.D., Executive Vice
President and CSO of SIBIA Neurosciences, Inc., 619-452-5892,
ext. 229, jmckelvy@sibia.com
|
